Bristol Myers Squibb Company (NYSE:BMY) Raises Dividend to $0.63 Per Share

Bristol Myers Squibb Company (NYSE:BMY) announced a quarterly dividend on Wednesday, December 10th. Stockholders of record on Friday, January 2nd will be paid a dividend of 0.63 per share by the biopharmaceutical company on Monday, February 2nd. This represents a c) dividend on an annualized basis and a dividend yield of 4.9%. The ex-dividend date is Friday, January 2nd. This is a 1.6% increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62.

Bristol Myers Squibb has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 17 consecutive years. Bristol Myers Squibb has a payout ratio of 40.9% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Bristol Myers Squibb to earn $6.09 per share next year, which means the company should continue to be able to cover its $2.48 annual dividend with an expected future payout ratio of 40.7%.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock traded up $0.10 on Thursday, hitting $51.31. The stock had a trading volume of 1,688,270 shares, compared to its average volume of 13,876,883. The stock has a market cap of $104.44 billion, a price-to-earnings ratio of 17.34, a price-to-earnings-growth ratio of 7.75 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.33. The business’s 50 day moving average is $46.55 and its two-hundred day moving average is $46.87.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same period last year, the firm posted $1.80 EPS. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts forecast that Bristol Myers Squibb will post 6.74 EPS for the current year.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.